Display options
Cite
Gonulalan G, Tanrıkulu Y. Relationship of dehydroepiandrosterone sulfate levels with atherosclerosis in patients with subclinical hypothyroidism. Wien Klin Wochenschr. 2021;doi: 10.1007/s00508-021-01844-9.
Gonulalan, G., & Tanrıkulu, Y. (2021). Relationship of dehydroepiandrosterone sulfate levels with atherosclerosis in patients with subclinical hypothyroidism. Wiener klinische Wochenschrift, . https://doi.org/10.1007/s00508-021-01844-9
Gonulalan, Gulsum, and Tanrıkulu, Yusuf. "Relationship of dehydroepiandrosterone sulfate levels with atherosclerosis in patients with subclinical hypothyroidism." Wiener klinische Wochenschrift vol. (2021). doi: https://doi.org/10.1007/s00508-021-01844-9
Gonulalan G, Tanrıkulu Y. Relationship of dehydroepiandrosterone sulfate levels with atherosclerosis in patients with subclinical hypothyroidism. Wien Klin Wochenschr. 2021 Mar 31; doi: 10.1007/s00508-021-01844-9. Epub 2021 Mar 31. PMID: 33788012.
Copy Download .nbib Format: NLM
Share it on

Wien Klin Wochenschr. 2021 Mar 31; doi: 10.1007/s00508-021-01844-9. Epub 2021 Mar 31.

Relationship of dehydroepiandrosterone sulfate levels with atherosclerosis in patients with subclinical hypothyroidism.

Wiener klinische Wochenschrift

Gulsum Gonulalan, Yusuf Tanrıkulu

Affiliations

  1. School of Medicine, Medicana Konya Hospital, Department of Endocrinology and Metabolism, KTO Karatay University, Konya, Turkey. [email protected].
  2. School of Medicine, Medicana Konya Hospital, Department of General Surgery, KTO Karatay University, Konya, Turkey. [email protected].
  3. School of Medicine, Medicana Konya Hospital, Department of Endocrinology and Metabolism, KTO Karatay University, Konya, Turkey.
  4. School of Medicine, Medicana Konya Hospital, Department of General Surgery, KTO Karatay University, Konya, Turkey.

PMID: 33788012 DOI: 10.1007/s00508-021-01844-9

Abstract

BACKGROUND: Subclinical hypothyroidism is related with increased risk of cardiovascular diseases. The decreased levels of dehydroepiandrosterone sulphate (DHEA-S) are associated with hyperlipidemia, atherosclerosis and obesity. The lower levels of DHEA‑S might be an important factor in development of atherosclerosis in subclinical hypothyroidism.

METHODS: A total of 126 patients (62 with subclinical hypothyroidism and 64 healthy individuals) were included in this prospectively designed study between January 2017 and December 2019. All individuals were evaluated according to DHEA‑S levels, carotid intima media thickness (CIMT) and anthropometric measurements. Blood samples were obtained from patients after 8 h fasting. The groups were statistically compared.

RESULTS: The mean ages of control group and patients with subclinical hypothyroidism were 36.9 ± 11.0 years and 39.6 ± 11.0 years, respectively (p = 0.165). The mean waist circumferences in controls and patients were 89 ± 10.7 cm and 91.3 ± 11.1 cm, respectively (p < 0.001). The DHEA‑S levels were 131.04 ± 96.02 µg/dl in patients, and these levels were significantly decreased in patients with subclinical hypothyroidism (p = 0.024). The levels of DHEA‑S were found to be negatively correlated with CIMT (p < 0.001, c = 0.406).

CONCLUSIONS: The early detection of cardiac and metabolic dysfunctions in subclinical hypothyroidism is important to avoid complications. We found a negative correlation between DHEA‑S levels and metabolic and cardiovascular risk factors in subclinical hypothyroidism. We believe that our results would attract more attention to the studies investigating relationships between DHEA‑S levels and cardiovascular complications of subclinical hypothyroidism.

Keywords: Endothelial dysfunction; Hypothyroidism; Inflammation; Subclinical atherosclerosis; Thyroid

References

  1. Cooper DS. Clinical practice subclinical hypothyroidism. N Eng J Med. 2001;345(4):260–5. - PubMed
  2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–34. - PubMed
  3. Saif A, Mousa S, Assem M, Tharwat N, Abdelhamid A. Endothelial dysfunction and the risk of atherosclerosisin overt and subclinical hypothyroidism. Endocr Connect. 2018;7(10):1075–80. - PubMed
  4. Perrini S, Laviola L, Natalicchio A, Giorgino F. Associated hormonal declines in aging: DHEA‑S. J Endocrinol Invest. 2005;28(3):85–93. - PubMed
  5. Barrett-Connor E, Khaw KT, Yen SS. Aprospective study of dehydroepiandrosteronesulfate, mortality and cardiovascular disease. N Engl J Med. 1986;315(24):1519–24. - PubMed
  6. Cappola AR, O’Meara ES, Guo W, Bartz TM, Fried LP, Newman AB. Trajectories of dehydroepiandrosteronesulfate predict mortality in older adults: the cardiovascular health study. J Gerontol A Biol Sci Med Sci. 2009;64(12):1268–74. - PubMed
  7. Page JH, Ma J, Rexrode KM, Rifai N, Manson JE, Hankinson SE. Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem. 2008;54(7):1190–6. - PubMed
  8. Shufelt C, Bretsky P, Almeida CM, et al. DHEA‑S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health-National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010;95(11):4985–92. - PubMed
  9. Kahonen MH, Tilvis RS, Jolkkonen J, Pitkälä K, Härkönen M. Predictors and clinical significance of declining plasma dehydroepiandrosteronesulfate in old age. Aging. 2000;12(4):308–14. - PubMed
  10. Legrain S, Girard L. Pharmacology and therapeutic effect of dehydroepiandrosterone in older subjects. Drugs Aging. 2003;20(13):949–67. - PubMed
  11. Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1996;81(1):59–64. - PubMed
  12. Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1(2):106–16. - PubMed
  13. World Health Organization. Waist circumference and waist-hipratio. Report of a WHO expert consultation. December 8–11. Geneva: WHO; 2008. - PubMed
  14. Imga NN, Topcuoglu C, Berker D, Turhan T. Serum amyloid A, paraoxonase-I activity and apolipoprotein concentrations as biomarkers of subclinical atherosclerosis risk in adrenal incidentaloma patients. Arch Med Res. 2018;49(3):182–90. - PubMed
  15. Ojamaa K, Sabet A, Kenessey A, Shenoy R, Klein I. Regulation of rat cardiac gene expression by thyroid hormone is rapidandchamberspecific. Endocrinology. 1999;140(7):3170–6. - PubMed
  16. Cerbone M, Capalbo D, Wasniewska M, et al. Cardiovascular risk factors in children with long-standing untreated idiopathic subclinical hypothyroidism. J Clin Endocrinol Metab. 2014;99(8):2697–703. - PubMed
  17. Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab. 2010;95(8):3614–7. - PubMed
  18. Asvold BO, Bjoro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and nonsmokers. J Clin Endocrinol Metab. 2009;94(12):5023–7. - PubMed
  19. Mousa U, Bozkuş Y, Kut A, Demir CC, Tutuncu NB. Fat distribution and metabolic profile in subjects with hashimoto’s thyroiditis. Acta Endocrinol. 2018;14(1):105–12. - PubMed
  20. Yasar HY, Topaloglu O, Demirpence M, Ceyhan BO, Guclu F. Is subclinical hypothyroidism in patients with polycystic ovary syndrome associated with BMI? Acta Endocrinol. 2016;12(4):431–6. - PubMed
  21. Rothwell PM. The Interrelation between carotid, femoral and coronary artery disease. Eur Heart J. 2001;22(1):11–4. - PubMed
  22. Mukherjee D, Yadav JS. Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and responseto risk factormodification. Am Heart J. 2002;144(5):753–9. - PubMed
  23. Dhatariya KK, Nair KS. Dehydroepiandrosterone: is there a role forreplacement? Mayo Clin Proc. 2003;78(10):1257–1253. - PubMed
  24. Hernandez-Morante JJ, Milagro F, Gabaldon JA, Martinez JA, Zamora S, Garaulet M. Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur J Endocrinol. 2006;155(4):593–4. - PubMed
  25. Wang YD, Tao MF, Cheng WW, Liu XH, Wan XP, Cui K. Dehydroepiandrosterone indirectly inhibits human osteoclastic resorption via activating osteoblastic viability by the MAPK pathway. Chin Med J. 2012;125(7):1230–5. - PubMed
  26. Benelli C, Michel O, Michel R. Effect of thyroidectomy on pregnenolone and progesterone biosynthesis in rat adrenal. J Steroid Biochem. 1982;16(6):749–54. - PubMed
  27. Ohlsson C, Labrie F, Barrett-Connor E, et al. Low serum levels of dehydroepiandrosteronesulfatepredictall-causeandcardiovascularmortality in elderlySwedish men. J Clin Endocrinol Metab. 2010;95(9):4406–14. - PubMed
  28. Jimenez MC, Sun Q, Schurks M, et al. Low dehydroepiandrosteronesulfate is associated with increased risk of ischemic stroke among women. Stroke. 2013;44(7):1784–9. - PubMed
  29. Browne ES, Porter JR, Correa G, Abadie J, Svec F. Dehydroepiandrosterone regulation of the hepatic glucocorticoid receptor in the Zucker rat. The obesity research program. J Steroid Biochem Mol Biol. 1993;45(6):517–24. - PubMed
  30. Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Rev. 1999;30(3):264–98. - PubMed
  31. Nilsson T, Mellbring G, Damber JE. Relationships between tissue plasmino gen activator, steroid hormones, and deep vein thrombosis. Acta Chir Scand. 1985;151(6):515–9. - PubMed
  32. Beer NA, Jakubowicz DJ, Matt DW, Beer RM, Nestler JE. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci. 1996;311(5):205–10. - PubMed
  33. Gordon GB, Newitt JA, Shantz LM, Weng DE, Talalay P. Inhibition of theconversion of 3T3 fibroblastclonesto adipocytes by dehydroepiandrosterone and related anticarcinogenic steroids. Cancer Res. 1986;46(7):3389–95. - PubMed
  34. Akyürek N, Atabek ME, Eklioglu BS, Alp H. Is there a relationship between cardiovascular risk factors and dehydroepiandrosteronesulfate levels in childhood obesity? J Pediatr Endocrinol Metab. 2015;28(5–6):545–50. - PubMed

Publication Types